Divyaswathi Citla-Sridhar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Divyaswathi Citla-Sridhar has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Sanjay Ahuja
Innovative Hematology, inc., Indianapolis, Indiana, United States
6 shared publications- Shelley E. Crary
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
3 shared publications - Andrew William Brown
Arkansas Children’s Research Institute, Little Rock, AR, USA
2 shared publications Daniel Isaac
College of Human Medicine, Division of Hematology/Oncology Michigan State University Lansing Michigan USA
2 shared publicationsJin-Ran Chen
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
2 shared publications- Lalitha Nayak
University Hospitals Cleveland Medical Center, Cleveland, OH
2 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by American Society of Hematology in Blood Advances
Response to " Bone Mineral Density in Hemophilia & VWD"
- 19 October 2026
- Published by American Society of Hematology in Blood Advances
Open AccessResponse to " Bone Mineral Density in Hemophilia & VWD"
- 16 October 2026
- Published by American Society of Hematology in Blood
Cases of High-Titer Inhibitor Formation After AAV Gene Therapy for Hemophilia A
Gene therapy for hemophilia A (HA) aims to provide durable hemostatic control and reduce treatment burden, but AAV-based products to date have limitations: inconsistent peak expression, declining factor levels, and immunogenicity causing transaminitis and expression loss. ASC618 (ASC Therapeutics, Milpitas, CA, USA) was developed as a second-generation gene therapy product to overcome some of these limitations, using ET3, a bioengineered chimeric human/porcine B-domain-deleted FVIII transgene, paired with a minimal liver promoter and liver codon optimization. In a phase 1/2 trial (NCT04676048), two patients received ASC618. Despite initial factor expression, both developed high-titer FVIII inhibitors and are now maintained on emicizumab prophylaxis. Although inhibitor titers have declined, both remain high-titer nearly two years after a single infusion. The best explanation for inhibitor formation is that the novel FVIII with the human-porcine hybrid construct (ET3) contained epitopes for which these patients had not developed tolerance despite both having more than 1000 exposure days to exogenous FVIII in the past. Although this trial has been halted, these cases provide important lessons for the development of future hemophilia gene therapies. They highlight the need for careful immunogenicity assessment when using bioengineered transgenes, even in previously treated patients with extensive factor VIII exposure.
- 16 October 2026
- Published by American Society of Hematology in Blood
Cases of High-Titer Inhibitor Formation After AAV Gene Therapy for Hemophilia A
Gene therapy for hemophilia A (HA) aims to provide durable hemostatic control and reduce treatment burden, but AAV-based products to date have limitations: inconsistent peak expression, declining factor levels, and immunogenicity causing transaminitis and expression loss. ASC618 (ASC Therapeutics, Milpitas, CA, USA) was developed as a second-generation gene therapy product to overcome some of these limitations, using ET3, a bioengineered chimeric human/porcine B-domain-deleted FVIII transgene, paired with a minimal liver promoter and liver codon optimization. In a phase 1/2 trial (NCT04676048), two patients received ASC618. Despite initial factor expression, both developed high-titer FVIII inhibitors and are now maintained on emicizumab prophylaxis. Although inhibitor titers have declined, both remain high-titer nearly two years after a single infusion. The best explanation for inhibitor formation is that the novel FVIII with the human-porcine hybrid construct (ET3) contained epitopes for which these patients had not developed tolerance despite both having more than 1000 exposure days to exogenous FVIII in the past. Although this trial has been halted, these cases provide important lessons for the development of future hemophilia gene therapies. They highlight the need for careful immunogenicity assessment when using bioengineered transgenes, even in previously treated patients with extensive factor VIII exposure.
- Open Access
- 21 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (16) , 5576-5586
Bone Mineral Density, Bone Remodeling Biomarkers, and Hemostatic Correlates in Hemophilia and von Willebrand Disease
Persons with hemophilia (PwH) have lower bone mineral density (BMD) and increased fracture risk, but data for persons with von Willebrand disease (PwVWD) are limited. Biological mechanisms underlying altered bone health in bleeding disorders remain poorly defined. Primary aim: compare total BMD among PwH, PwVWD, and healthy controls. Secondary aim: characterize bone remodeling biomarkers and examine associations between BMD and simultaneous thrombin-plasmin generation (STP). In a three-group, cross-sectional observational study of participants aged 5-45 years (34 PwH, 45 PwVWD, 30 controls), total BMD and bone mineral content (BMC) were assessed by dual-energy X-ray absorptiometry ; trabecular and cortical parameters were assessed by peripheral quantitative computed tomography ; serum procollagen type 1 N-terminal propeptide and C-terminal telopeptide of type I collagen were measured as markers of bone formation and resorption; and STP assays quantified coagulation and fibrinolytic activity. Associations with BMD Z-scores were evaluated using linear and multivariable regression. PwVWD had significantly lower BMD Z-scores compared with controls, while PwH showed a similar but nonsignificant trend. Both PwH and PwVWD had significantly lower BMC. In multivariable models, higher thrombin generation was associated with higher BMD Z-scores, whereas higher plasmin generation was associated with lower BMD Z-scores. In multivariable models, STP parameters were associated with BMD and accounted for a greater proportion of variance than models including clinical factors or bone turnover markers. PwH and PwVWD exhibit measurable deficits in bone health. Observed associations between thrombin-plasmin dynamics and BMD are hypothesis-generating and support further longitudinal and mechanistic studies of hemostasis-bone relationships.
- 21 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (16) , 5576-5586
Open AccessBone Mineral Density, Bone Remodeling Biomarkers, and Hemostatic Correlates in Hemophilia and von Willebrand Disease
Persons with hemophilia (PwH) have lower bone mineral density (BMD) and increased fracture risk, but data for persons with von Willebrand disease (PwVWD) are limited. Biological mechanisms underlying altered bone health in bleeding disorders remain poorly defined. Primary aim: compare total BMD among PwH, PwVWD, and healthy controls. Secondary aim: characterize bone remodeling biomarkers and examine associations between BMD and simultaneous thrombin-plasmin generation (STP). In a three-group, cross-sectional observational study of participants aged 5-45 years (34 PwH, 45 PwVWD, 30 controls), total BMD and bone mineral content (BMC) were assessed by dual-energy X-ray absorptiometry ; trabecular and cortical parameters were assessed by peripheral quantitative computed tomography ; serum procollagen type 1 N-terminal propeptide and C-terminal telopeptide of type I collagen were measured as markers of bone formation and resorption; and STP assays quantified coagulation and fibrinolytic activity. Associations with BMD Z-scores were evaluated using linear and multivariable regression. PwVWD had significantly lower BMD Z-scores compared with controls, while PwH showed a similar but nonsignificant trend. Both PwH and PwVWD had significantly lower BMC. In multivariable models, higher thrombin generation was associated with higher BMD Z-scores, whereas higher plasmin generation was associated with lower BMD Z-scores. In multivariable models, STP parameters were associated with BMD and accounted for a greater proportion of variance than models including clinical factors or bone turnover markers. PwH and PwVWD exhibit measurable deficits in bone health. Observed associations between thrombin-plasmin dynamics and BMD are hypothesis-generating and support further longitudinal and mechanistic studies of hemostasis-bone relationships.
- Open Access
- 22 October 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (7) , 103230
Venous thromboembolism in obese hormonal contraceptive users: a large national database study
- 22 October 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (7) , 103230
Open AccessVenous thromboembolism in obese hormonal contraceptive users: a large national database study
- 2 October 2025
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 47 (8) , e391-e397
Unclassified Versus Well-defined Platelet Function Disorders: A Multicenter Comparison of Bleeding Patterns and Treatment
Introduction: Platelet function disorders (PFDs) are caused by abnormalities in platelet receptors, granules, and signaling pathways. While severe conditions like Glanzmann Thrombasthenia (GT) and Bernard-Soulier Syndrome (BSS) have well-characterized bleeding phenotypes, other PFDs remain less defined. This study aimed to describe the bleeding phenotype in different PFDs at the time of diagnosis and during longitudinal follow-up and compare bleeding symptoms and health care utilization for bleed management. Methods: This retrospective multicenter study analyzed data from 129 patients diagnosed with PFDs at 3 Hemophilia Treatment Centers in the United States from 2015 to 2020. Data included demographics, bleeding symptoms, and treatment utilization. Statistical comparisons of bleeding symptoms, frequency, and treatment across PFDs were performed using the χ 2 or the Fisher exact tests. Results: Among 129 patients, 8 had GT, 2 had BSS, 40 had platelet storage pool disorder, 7 had platelet secretion defect, and 72 had PFD not otherwise specified (NOS). Epistaxis was the most common symptom at diagnosis, except in platelet secretion defects, where soft tissue bleeding predominated. Heavy menstrual bleeding affected 31.7% of females. Over a 5-year period, epistaxis remained frequent in GT and PFD NOS. GT had the highest treatment burden, with 86.2% of bleeds requiring treatment. Hospitalizations were significantly greater in GT and platelet secretion defects. Conclusion: Individuals with PFD NOS and platelet secretion defects can experience serious bleeding. Life-threatening bleeds occur in PFDs beyond GT and BSS, necessitating thorough evaluation, close follow-up, and careful perioperative planning. Unclassified platelet disorders require further evaluation along with genetic testing to prevent excessive blood loss.
- 2 October 2025
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 47 (8) , e391-e397
Unclassified Versus Well-defined Platelet Function Disorders: A Multicenter Comparison of Bleeding Patterns and Treatment
Introduction: Platelet function disorders (PFDs) are caused by abnormalities in platelet receptors, granules, and signaling pathways. While severe conditions like Glanzmann Thrombasthenia (GT) and Bernard-Soulier Syndrome (BSS) have well-characterized bleeding phenotypes, other PFDs remain less defined. This study aimed to describe the bleeding phenotype in different PFDs at the time of diagnosis and during longitudinal follow-up and compare bleeding symptoms and health care utilization for bleed management. Methods: This retrospective multicenter study analyzed data from 129 patients diagnosed with PFDs at 3 Hemophilia Treatment Centers in the United States from 2015 to 2020. Data included demographics, bleeding symptoms, and treatment utilization. Statistical comparisons of bleeding symptoms, frequency, and treatment across PFDs were performed using the χ 2 or the Fisher exact tests. Results: Among 129 patients, 8 had GT, 2 had BSS, 40 had platelet storage pool disorder, 7 had platelet secretion defect, and 72 had PFD not otherwise specified (NOS). Epistaxis was the most common symptom at diagnosis, except in platelet secretion defects, where soft tissue bleeding predominated. Heavy menstrual bleeding affected 31.7% of females. Over a 5-year period, epistaxis remained frequent in GT and PFD NOS. GT had the highest treatment burden, with 86.2% of bleeds requiring treatment. Hospitalizations were significantly greater in GT and platelet secretion defects. Conclusion: Individuals with PFD NOS and platelet secretion defects can experience serious bleeding. Life-threatening bleeds occur in PFDs beyond GT and BSS, necessitating thorough evaluation, close follow-up, and careful perioperative planning. Unclassified platelet disorders require further evaluation along with genetic testing to prevent excessive blood loss.
- 7 March 2025
- Published by Wiley in Haemophilia
- Vol. 31 (3) , 519-525
Bone Health Screening in Persons With Bleeding Disorders: A Survey of United States Haemophilia Treatment Centres
Background: Despite reports of elevated rates of osteoporosis and fractures in persons with haemophilia (PwH) and von Willebrand disease (PwVWD), routine bone health screening using dual‐energy X‐ray absorptiometry (DEXA) scans is not consistently implemented for this population across all Haemophilia Treatment Centres (HTCs) in the United States. Objectives: The primary aim of this study was to examine rates of screening for bone health in PwH and PwVWD with vitamin D levels and DEXA scans. Methods: We conducted a survey of all federally funded HTCs nationwide from June 2023 to August 2023. Nine multiple‐choice questions were developed to explore the roles of HTC providers and their current practices for bone health assessment. Results: The survey achieved a response rate of 44.8% (66 out of 147 HTCs). Among the responding centres, 21 HTCs (31.8%) reported routinely screening for vitamin D deficiency during annual comprehensive visits, while 13.6% ( n = 9) performed regular bone health screenings using DEXA scans. Of these nine centres, three were adult HTCs and six were lifespan HTCs. DEXA scans were ordered either by physicians at the HTC ( n = 5, 55.5%) or patients were referred to primary care providers, endocrinologists, or other specialists ( n = 4, 44.4%). The top three indications for DEXA scans among the responding HTCs included HIV ( n = 7, 77.7%), low physical activity or immobility ( n = 6, 66.7%), fractures after a minor fall or injury in patients under 50 years of age ( n = 5, 55.5%) and vitamin D deficiency ( n = 5, 55.5%). These findings underscore the need for specific standardized screening guidelines to optimize bone health screening in PwH and PwVWD.
- 7 March 2025
- Published by Wiley in Haemophilia
- Vol. 31 (3) , 519-525
Bone Health Screening in Persons With Bleeding Disorders: A Survey of United States Haemophilia Treatment Centres
Background: Despite reports of elevated rates of osteoporosis and fractures in persons with haemophilia (PwH) and von Willebrand disease (PwVWD), routine bone health screening using dual‐energy X‐ray absorptiometry (DEXA) scans is not consistently implemented for this population across all Haemophilia Treatment Centres (HTCs) in the United States. Objectives: The primary aim of this study was to examine rates of screening for bone health in PwH and PwVWD with vitamin D levels and DEXA scans. Methods: We conducted a survey of all federally funded HTCs nationwide from June 2023 to August 2023. Nine multiple‐choice questions were developed to explore the roles of HTC providers and their current practices for bone health assessment. Results: The survey achieved a response rate of 44.8% (66 out of 147 HTCs). Among the responding centres, 21 HTCs (31.8%) reported routinely screening for vitamin D deficiency during annual comprehensive visits, while 13.6% ( n = 9) performed regular bone health screenings using DEXA scans. Of these nine centres, three were adult HTCs and six were lifespan HTCs. DEXA scans were ordered either by physicians at the HTC ( n = 5, 55.5%) or patients were referred to primary care providers, endocrinologists, or other specialists ( n = 4, 44.4%). The top three indications for DEXA scans among the responding HTCs included HIV ( n = 7, 77.7%), low physical activity or immobility ( n = 6, 66.7%), fractures after a minor fall or injury in patients under 50 years of age ( n = 5, 55.5%) and vitamin D deficiency ( n = 5, 55.5%). These findings underscore the need for specific standardized screening guidelines to optimize bone health screening in PwH and PwVWD.
- Open Access
- 15 January 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 2 (3) , 100047
Risk factors for joint bleeding in severe hemophilia A and B: analysis of the Community Counts longitudinal surveillance cohort
- 15 January 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 2 (3) , 100047
Open AccessRisk factors for joint bleeding in severe hemophilia A and B: analysis of the Community Counts longitudinal surveillance cohort
- 16 June 2024
- Published by Wiley in Haemophilia
- Vol. 30 (5) , 1225-1226
A case of bruising and joint hypermobility: The need to consider genetic testing for platelet disorders
- 16 June 2024
- Published by Wiley in Haemophilia
- Vol. 30 (5) , 1225-1226
A case of bruising and joint hypermobility: The need to consider genetic testing for platelet disorders
- 5 April 2023
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 21 (7) , 1741-1743
Reproductive healthcare utilization in patients with bleeding disorders
- 5 April 2023
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 21 (7) , 1741-1743
Reproductive healthcare utilization in patients with bleeding disorders
- Open Access
- 22 April 2022
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 6 (3) , e12708
Thrombotic microangiopathies: An illustrated review
- 22 April 2022
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 6 (3) , e12708
Open AccessThrombotic microangiopathies: An illustrated review